Pemazyre (pemigatinib)

About Incyte

Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.

Therapeutic Areas

Other Cholangiocarcinoma Drugs